Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Evkeeza
Pharma
FDA says children age 5-11 now eligible for Regeneron's Evkeeza
Regeneron has gained an FDA approval for the use of Evkeeza in children ages 5 through 11 with homozygous familial hypercholesterolemia.
Kevin Dunleavy
Mar 22, 2023 10:39am
Regeneron's Evkeeza gets priority look for use in kids with HoFH
Nov 30, 2022 11:19am
Regeneron hands over Evkeeza rights to Ultragenyx outside US
Jan 7, 2022 10:05am
Regeneron's Evkeeza aces triglyceride control in some patients
May 16, 2021 9:33am
